FI961886A0 - Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit - Google Patents

Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit

Info

Publication number
FI961886A0
FI961886A0 FI961886A FI961886A FI961886A0 FI 961886 A0 FI961886 A0 FI 961886A0 FI 961886 A FI961886 A FI 961886A FI 961886 A FI961886 A FI 961886A FI 961886 A0 FI961886 A0 FI 961886A0
Authority
FI
Finland
Prior art keywords
dna
human kunitz
protease inhibitors
dna segment
type protease
Prior art date
Application number
FI961886A
Other languages
English (en)
Swedish (sv)
Other versions
FI961886A (fi
Inventor
Cindy A Sprecher
Walter Kisiel
Donald C Foster
Original Assignee
Zymogenetics Inc
Univ New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Univ New Mexico filed Critical Zymogenetics Inc
Publication of FI961886A0 publication Critical patent/FI961886A0/fi
Publication of FI961886A publication Critical patent/FI961886A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
FI961886A 1993-11-05 1996-05-03 Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit FI961886A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/147,710 US5455338A (en) 1993-11-05 1993-11-05 DNA encoding novel human kunitz-type inhibitors and methods relating thereto
PCT/US1994/012609 WO1995012674A1 (en) 1993-11-05 1994-11-02 Human kunitz-type protease inhibitors

Publications (2)

Publication Number Publication Date
FI961886A0 true FI961886A0 (fi) 1996-05-03
FI961886A FI961886A (fi) 1996-07-03

Family

ID=22522614

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961886A FI961886A (fi) 1993-11-05 1996-05-03 Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit

Country Status (12)

Country Link
US (7) US5455338A (fi)
EP (1) EP0726953B1 (fi)
JP (1) JP3201527B2 (fi)
KR (1) KR100243989B1 (fi)
CN (1) CN1073159C (fi)
AT (1) ATE262587T1 (fi)
AU (1) AU685190B2 (fi)
CA (1) CA2175797C (fi)
DE (1) DE69433647T2 (fi)
FI (1) FI961886A (fi)
NO (1) NO961812L (fi)
WO (1) WO1995012674A1 (fi)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6025329A (en) * 1995-08-09 2000-02-15 Toray Industries, Inc. Method for treating ophthalmic diseases
NZ331540A (en) 1996-03-11 1999-10-28 Bayer Ag Human bikunin
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
EP1374891B1 (en) * 1998-12-22 2008-09-10 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
WO2001009360A1 (en) * 1999-08-02 2001-02-08 Avigen, Inc. USE OF RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR (rAAV) FOR THE PREVENTION OF SMOOTH MUSCLE CELL PROLIFERATION IN A VASCULAR GRAFT
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) * 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US7544500B2 (en) * 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US20020132978A1 (en) * 2000-03-21 2002-09-19 Hans-Peter Gerber VEGF-modulated genes and methods employing them
AU2001296470A1 (en) 2000-10-02 2002-04-15 Marc D. Andelman Fringe-field capacitor electrode for electrochemical device
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7910550B2 (en) * 2004-04-16 2011-03-22 Stc.Unm Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7432238B2 (en) * 2004-04-16 2008-10-07 Stc.Unm Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CA2597325A1 (en) * 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
CA2924836A1 (en) 2005-12-29 2007-07-05 The Regents Of The University Of California Methods and compositions related to mutant kunitz domain i of tfpi-2
US20070278239A1 (en) * 2006-05-17 2007-12-06 Michele Vogt Sipping lid closure device and method of use
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
PT2915564T (pt) 2007-09-28 2021-02-09 Alexion Pharma Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
JP2011522538A (ja) * 2008-06-04 2011-08-04 タレクリス・バイオセラピユーテイクス・インコーポレーテツド プラスミン製造のための組成物、方法およびキット
JP5739816B2 (ja) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
EP2379600B2 (en) 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
ES2552337T3 (es) 2009-03-03 2015-11-27 Grifols Therapeutics Inc. Procedimientos para la preparación de plasminógeno
ES2607935T3 (es) 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
CN101588509B (zh) * 2009-06-23 2011-08-24 硅谷数模半导体（北京）有限公司 视频图像编码和解码方法
WO2011008885A1 (en) 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
LT2521568T (lt) 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011115712A2 (en) 2010-03-19 2011-09-22 Baxter International Inc Tfpi inhibitors and methods of use
BR112013017080A8 (pt) 2011-01-06 2023-05-09 Dyax Corp Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
US11448657B2 (en) * 2011-01-18 2022-09-20 Rambam Med-Tech Methods and kits for assessing Heparanase procoagulant activity, compositions comprising Heparanase, and methods for the treatment of coagulation-related disorders
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
EP3626254A1 (en) 2012-03-16 2020-03-25 University Health Network Soluble toso protein and its use in treating autoimmune disorders
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
AU2014228858A1 (en) * 2013-03-15 2015-09-10 The Regents Of The University Of California Dual reactivity potent Kunitz inhibitor of fibrinolysis
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
EP3565834A1 (en) 2017-01-04 2019-11-13 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3145385A1 (en) 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms
CN112206310B (zh) * 2020-09-23 2022-10-21 湖北医药学院 一组用于抑制补体的寄生绦虫多肽

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ213563A (en) * 1984-09-21 1991-08-27 Boehringer Ingelheim Int Anticoagulant proteins and pharmaceutical compositions
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5557518A (en) * 1994-04-28 1996-09-17 Citibank, N.A. Trusted agents for open electronic commerce
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US5884292A (en) * 1993-05-06 1999-03-16 Pitney Bowes Inc. System for smart card funds refill
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5578808A (en) * 1993-12-22 1996-11-26 Datamark Services, Inc. Data card that can be used for transactions involving separate card issuers
US5854975A (en) * 1994-12-23 1998-12-29 Freedom Wireless, Inc. Prepaid security cellular telecommunications system
US5722067A (en) * 1994-12-23 1998-02-24 Freedom Wireless, Inc. Security cellular telecommunications system
US5903633A (en) * 1995-03-27 1999-05-11 Smarttalk Teleservices, Inc. Method and apparatus for prepaid phone card activation and billing
US5684291A (en) * 1995-06-01 1997-11-04 American Express Trs Refundable prepaid telephone card
US5778313A (en) * 1995-12-08 1998-07-07 Cellexis International, Inc. Pre-paid cellular telephone system
US5892827A (en) * 1996-06-14 1999-04-06 Catalina Marketing International, Inc. Method and apparatus for generating personal identification numbers for use in consumer transactions
US5845259A (en) * 1996-06-27 1998-12-01 Electronic Consumer Concepts, L.L.C. Electronic coupon dispensing system
US5991749A (en) * 1996-09-11 1999-11-23 Morrill, Jr.; Paul H. Wireless telephony for collecting tolls, conducting financial transactions, and authorizing other activities
US5828740A (en) * 1996-11-14 1998-10-27 Sprint Communications Co., L.P. Prepaid calling card external/adjunct database processor
US5991380A (en) * 1997-10-21 1999-11-23 At&T Corp. Universal telecommunications services account
US6035025A (en) * 1998-01-07 2000-03-07 National Telemanagement Corporation System and method for a prepaid bundled telecommunications account
US7249054B2 (en) * 1998-06-18 2007-07-24 Keil Dean S System and method for debit account transactions
EP1105813A4 (en) * 1998-08-25 2001-10-10 Mobshop Inc ON-LINE MARKETING SYSTEM AND METHOD
US20030163425A1 (en) * 2002-02-26 2003-08-28 Cannon Thomas Calvin System for executing high-volume electronic bill payments

Also Published As

Publication number Publication date
US20040253686A1 (en) 2004-12-16
US6656746B2 (en) 2003-12-02
KR100243989B1 (ko) 2000-02-01
EP0726953B1 (en) 2004-03-24
US5455338A (en) 1995-10-03
KR960705850A (ko) 1996-11-08
NO961812L (no) 1996-07-05
CA2175797C (en) 2000-07-18
JPH09504696A (ja) 1997-05-13
AU685190B2 (en) 1998-01-15
CN1073159C (zh) 2001-10-17
WO1995012674A1 (en) 1995-05-11
US5914315A (en) 1999-06-22
AU8131294A (en) 1995-05-23
CA2175797A1 (en) 1995-05-11
DE69433647D1 (de) 2004-04-29
US20070092948A1 (en) 2007-04-26
EP0726953A1 (en) 1996-08-21
CN1139955A (zh) 1997-01-08
US5728674A (en) 1998-03-17
DE69433647T2 (de) 2004-08-05
US7541449B2 (en) 2009-06-02
NO961812D0 (no) 1996-05-03
JP3201527B2 (ja) 2001-08-20
ATE262587T1 (de) 2004-04-15
US20050004021A1 (en) 2005-01-06
FI961886A (fi) 1996-07-03
US20020098560A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
FI961886A (fi) Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit
WO1994012637A3 (en) Novel human amyloid protein precursor homologue and kunitz-type inhibitors
DK0663010T3 (da) Fremgangsmåde til forøgelse af sekretion af overudtrykte proteiner
ES2153037T3 (es) Lacasas purificadas de scytalidium y acidos nucleicos que las codifican.
FI934811A (fi) Stabiliserade enzymer och detergentfoereningar
PT765394E (pt) Lacases myceliophthora purificadas e acidos nucleicos que as codificam
ATE322279T1 (de) Pneumokokkengene, ihre fragmente, ihre expressionsprodukte und die verwendung der gene, fragmente und produkte
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
ATE484587T1 (de) Ldcam genannte moleküle
DE3587875D1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
ATE384787T1 (de) Tripeptidyl-aminopeptidase
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
NO974035D0 (no) En ny vestfaktor og en genetisk sekvens som koder for denne
ATE297750T1 (de) Verwendung von hsp70 protein
DK0981631T3 (da) Polypeptider, som har aminopeptidase-aktivitet, og nukleinsyrer, som koder for samme
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
NO972313L (no) Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav
NO930428L (no) Proteinstrukturen til plantetoksingelonin
DK0904356T3 (da) Aspergillus Oryzae 5-aminolevulinsyre-synthaser og nukleinsyrer, der koder disse
ATE340257T1 (de) Histonedeacetylase 9
DK0629238T3 (da) Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi
BR9815277A (pt) Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transformada, homólogo de soja, método para alterar o nìvel de expressão de um homólogo do ativador de transcrição pvalf de phaseolus vulgaris em uma célula vegetal, método de obtenção de um fragmento de ácido nucléico e produto
BR0107655A (pt) Polinucleotìdeo isolado, vetor de expressão recombinante, polipeptìdeo, célula, método para produzir o polipeptìdeo, e, composição farmacêutica
DK0788549T3 (da) Regulerende nukleinsyresekvenser og anvendelser
ATE213773T1 (de) In apoptosis beteiligte cysteine protease cmh-1 und dns-sequenzen dafür